Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group.
- Study design
- Randomized trial
- Population / model
- Human
- Published
- 2017-05-01
- Journal
- The New England journal of medicine
- Sample mentioned
- 120 children — Number stated in the abstract; not independently verified.
Reviewed study note
What this study reported
The tested formulation reduced convulsive-seizure frequency relative to placebo; adverse events were more frequent.
- Population
- 120 children and young adults with Dravet syndrome and drug-resistant seizures.
- Studied preparation
- Purified CBD oral solution added to existing antiseizure treatment.
- Interpretation limit
- A specific severe epilepsy population and prescription-style formulation; findings do not establish benefits or safety of retail CBD oils.
From the author abstract
“The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 …”
A short attributed excerpt. Read the full abstract and original paper for methods, results and limitations.
Outcome summaries · provisional
Selected source sets; evidence confidence remains ungraded.
Citation and indexing details
PMID 28538134
Publication types: Journal Article; Multicenter Study; Randomized Controlled Trial
Topic tags: Epilepsy
Metadata checked 2026-11-04. Study design and model tags follow indexing and explicit abstract terms. Citation counts are not evidence of benefit. An available full text does not by itself permit image reuse.